News

September 20, 2019September 20, 2019

FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome, Acute Myeloid Leukemia

News

Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and myelodysplastic ... Read more

September 18, 2019

First-line Imfinzi-Chemo Therapy Extends Survival of Patients with Aggressive Lung Cancer, Phase 3 Trial Shows

News

Adding the immune checkpoint inhibitor Imfinzi (durvalumab) to standard chemotherapy care significantly extends the survival of patients with untreated extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung ... Read more

September 17, 2019September 17, 2019

Keytruda and Inlyta Combo Approved in Europe for Untreated Advanced Kidney Cancer

News

The European Commission has approved a combination of Keytruda (pembrolizumab) with Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on ... Read more

September 13, 2019

Nanotechnology May Help Get Immunotherapy Into the Brain, Mouse Study Says

News

Immunotherapies have shown little efficacy in brain cancers due to their inability to cross the blood-brain barrier. Now, however, researchers have developed a new nanotechnology approach that allowed immune checkpoint ... Read more

September 11, 2019

FDA Grants Orphan Drug Status to BioXcel’s BXCL701 as Potential AML Treatment

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BXCL701, one of BioXcel Therapeutics’ lead immunotherapies for the treatment of acute myeloid leukemia (AML). Orphan drug ... Read more

September 10, 2019

Health Canada and European Commission OK Tecentriq-Chemo Combo for Aggressive Lung Cancer

News

Health Canada and the European Commission have approved Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin plus etoposide) as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), an ... Read more

September 4, 2019

Trial of Targeted Radiation Therapy, CLR 131, in Children with Advanced Cancers Moving to Higher Dose

News

Cellectar Biosciences announced that a second and higher dose of its investigational radiotherapeutic compound, CLR 131, was cleared for use in its ongoing CLOVER-2 study in children with advanced solid ... Read more

September 3, 2019

Imfinzi-Tremelimumab Combo Fails to Prolong Overall Survival in Metastatic NSCLC, Phase 3 Trial Shows

News

A combination of tremelimumab plus Imfinzi (durvalumab) is no better than standard chemotherapy at extending the survival of people with metastatic non-small cell lung cancer (NSCLC) with a high tumor ... Read more

August 30, 2019

Pexa-Vec Combo Unlikely to Benefit Advanced Liver Cancer Patients in Phase 3 Trial, Monitoring Group Says

News

Adding the cancer vaccine Pexa-Vec to Nexavar (sorafenib), a standard of care, is not likely to improve overall survival of patients with advanced liver cancer, an interim analysis by the independent ... Read more

August 28, 2019

$102.2M Pelotonia Gift to Help Establish Immuno-Oncology Institute at OSU

News

A $102.2 million Pelotonia donation will help establish an institute at Ohio State University (OSU) that will focus exclusively on groundbreaking immuno-oncology therapies and cures for cancer. Disbursed over five years, ... Read more